Mitogen	0	7	B-Gene_or_gene_product
-	7	8	I-Gene_or_gene_product
activated	8	17	I-Gene_or_gene_product
protein	18	25	I-Gene_or_gene_product
kinase	26	32	I-Gene_or_gene_product
kinase	33	39	I-Gene_or_gene_product
signaling	40	49	O
promotes	50	58	O
growth	59	65	O
and	66	69	O
vascularization	70	85	O
of	86	88	O
fibrosarcoma	89	101	B-Pathological_formation
.	101	102	O

We	104	106	O
hypothesized	107	119	O
that	120	124	O
signaling	125	134	O
through	135	142	O
multiple	143	151	O
mitogen	152	159	B-Gene_or_gene_product
-	159	160	I-Gene_or_gene_product
activated	160	169	I-Gene_or_gene_product
protein	170	177	I-Gene_or_gene_product
kinase	178	184	I-Gene_or_gene_product
(	185	186	I-Gene_or_gene_product
MAPK	186	190	I-Gene_or_gene_product
)	190	191	I-Gene_or_gene_product
kinase	192	198	I-Gene_or_gene_product
(	199	200	O
MKK	200	203	B-Gene_or_gene_product
)	203	204	O
pathways	205	213	O
is	214	216	O
essential	217	226	O
for	227	230	O
the	231	234	O
growth	235	241	O
and	242	245	O
vascularization	246	261	O
of	262	264	O
soft	265	269	B-Pathological_formation
-	269	270	I-Pathological_formation
tissue	270	276	I-Pathological_formation
sarcomas	277	285	I-Pathological_formation
,	285	286	O
which	287	292	O
are	293	296	O
malignant	297	306	O
tumors	307	313	B-Pathological_formation
derived	314	321	O
from	322	326	O
mesenchymal	327	338	B-Tissue
tissues	339	346	I-Tissue
.	346	347	O

We	348	350	O
tested	351	357	O
this	358	362	O
using	363	368	O
HT	369	371	B-Cell
-	371	372	I-Cell
1080	372	376	I-Cell
,	376	377	O
NCI	378	381	B-Cell
,	381	382	O
and	383	386	O
Shac	387	391	B-Cell
fibrosarcoma	392	404	I-Cell
-	404	405	I-Cell
derived	405	412	I-Cell
cell	413	417	I-Cell
lines	418	423	I-Cell
and	424	427	O
anthrax	428	435	B-Organism
lethal	436	442	B-Drug_or_compound
toxin	443	448	I-Drug_or_compound
(	449	450	O
LeTx	450	454	B-Drug_or_compound
)	454	455	O
,	455	456	O
a	457	458	O
bacterial	459	468	O
toxin	469	474	O
that	475	479	O
inactivates	480	491	O
MKKs	492	496	B-Gene_or_gene_product
.	496	497	O

Western	498	505	O
blots	506	511	O
confirmed	512	521	O
that	522	526	O
LeTx	527	531	B-Drug_or_compound
treatment	532	541	O
reduced	542	549	O
the	550	553	O
levels	554	560	O
of	561	563	O
phosphorylated	564	578	O
extracellular	579	592	B-Gene_or_gene_product
signal	593	599	I-Gene_or_gene_product
-	599	600	I-Gene_or_gene_product
regulated	600	609	I-Gene_or_gene_product
kinase	610	616	I-Gene_or_gene_product
and	617	620	O
p38	621	624	B-Gene_or_gene_product
MAPK	625	629	I-Gene_or_gene_product
in	630	632	O
vitro	633	638	O
.	638	639	O

Although	640	648	O
short	649	654	O
treatments	655	665	O
with	666	670	O
LeTx	671	675	B-Drug_or_compound
only	676	680	O
modestly	681	689	O
affected	690	698	O
cell	699	703	B-Cell
proliferation	704	717	O
,	717	718	O
sustained	719	728	O
treatment	729	738	O
markedly	739	747	O
reduced	748	755	O
cell	756	760	B-Cell
numbers	761	768	O
.	768	769	O

LeTx	770	774	B-Drug_or_compound
also	775	779	O
substantially	780	793	O
inhibited	794	803	O
the	804	807	O
extracellular	808	821	O
release	822	829	O
of	830	832	O
angioproliferative	833	851	O
factors	852	859	O
including	860	869	O
vascular	870	878	B-Gene_or_gene_product
endothelial	879	890	I-Gene_or_gene_product
growth	891	897	I-Gene_or_gene_product
factor	898	904	I-Gene_or_gene_product
,	904	905	O
interleukin	906	917	B-Gene_or_gene_product
-	917	918	I-Gene_or_gene_product
8	918	919	I-Gene_or_gene_product
,	919	920	O
and	921	924	O
basic	925	930	B-Gene_or_gene_product
fibroblast	931	941	I-Gene_or_gene_product
growth	942	948	I-Gene_or_gene_product
factor	949	955	I-Gene_or_gene_product
.	955	956	O

Similar	957	964	O
results	965	972	O
were	973	977	O
obtained	978	986	O
with	987	991	O
cell	992	996	B-Cell
lines	997	1002	O
derived	1003	1010	O
from	1011	1015	O
malignant	1016	1025	B-Pathological_formation
fibrous	1026	1033	I-Pathological_formation
histiocytomas	1034	1047	I-Pathological_formation
,	1047	1048	O
leiomyosarcomas	1049	1064	B-Pathological_formation
,	1064	1065	O
and	1066	1069	O
liposarcomas	1070	1082	B-Pathological_formation
.	1082	1083	O

In	1084	1086	O
vivo	1087	1091	O
,	1091	1092	O
LeTx	1093	1097	B-Drug_or_compound
decreased	1098	1107	O
MAPK	1108	1112	B-Gene_or_gene_product
activity	1113	1121	O
and	1122	1125	O
blocked	1126	1133	O
fibrosarcoma	1134	1146	B-Pathological_formation
growth	1147	1153	O
.	1153	1154	O

Growth	1155	1161	O
inhibition	1162	1172	O
correlated	1173	1183	O
with	1184	1188	O
decreased	1189	1198	O
cellular	1199	1207	B-Cell
proliferation	1208	1221	O
and	1222	1225	O
extensive	1226	1235	O
necrosis	1236	1244	O
,	1244	1245	O
and	1246	1249	O
it	1250	1252	O
was	1253	1256	O
accompanied	1257	1268	O
by	1269	1271	O
a	1272	1273	O
decrease	1274	1282	O
in	1283	1285	O
tumor	1286	1291	B-Pathological_formation
mean	1292	1296	O
vessel	1297	1303	B-Multi-tissue_structure
density	1304	1311	O
as	1312	1314	O
well	1315	1319	O
as	1320	1322	O
a	1323	1324	O
reduction	1325	1334	O
in	1335	1337	O
serum	1338	1343	B-Organism_substance
expression	1344	1354	O
of	1355	1357	O
angioproliferative	1358	1376	O
cytokines	1377	1386	O
.	1386	1387	O

Vital	1388	1393	O
imaging	1394	1401	O
using	1402	1407	O
high	1408	1412	O
-	1412	1413	O
resolution	1413	1423	O
ultrasound	1424	1434	O
enhanced	1435	1443	O
with	1444	1448	O
contrast	1449	1457	O
microbubbles	1458	1470	O
revealed	1471	1479	O
that	1480	1484	O
the	1485	1488	O
effects	1489	1496	O
of	1497	1499	O
LeTx	1500	1504	B-Drug_or_compound
on	1505	1507	O
tumor	1508	1513	B-Pathological_formation
perfusion	1514	1523	O
were	1524	1528	O
remarkably	1529	1539	O
rapid	1540	1545	O
(	1546	1547	O
less	1548	1552	O
than	1553	1557	O
24	1558	1560	O
h	1561	1562	O
)	1562	1563	O
and	1564	1567	O
resulted	1568	1576	O
in	1577	1579	O
a	1580	1581	O
marked	1582	1588	O
reduction	1589	1598	O
of	1599	1601	O
perfusion	1602	1611	O
within	1612	1618	O
the	1619	1622	O
tumor	1623	1628	B-Pathological_formation
but	1629	1632	O
not	1633	1636	O
in	1637	1639	O
nontumor	1640	1648	B-Tissue
tissues	1649	1656	I-Tissue
.	1656	1657	O

These	1658	1663	O
results	1664	1671	O
are	1672	1675	O
consistent	1676	1686	O
with	1687	1691	O
our	1692	1695	O
initial	1696	1703	O
hypothesis	1704	1714	O
and	1715	1718	O
lead	1719	1723	O
us	1724	1726	O
to	1727	1729	O
propose	1730	1737	O
that	1738	1742	O
MKK	1743	1746	B-Gene_or_gene_product
inhibition	1747	1757	O
by	1758	1760	O
LeTx	1761	1765	B-Drug_or_compound
is	1766	1768	O
a	1769	1770	O
broadly	1771	1778	O
effective	1779	1788	O
strategy	1789	1797	O
for	1798	1801	O
targeting	1802	1811	O
neovascularization	1812	1830	O
in	1831	1833	O
fibrosarcomas	1834	1847	B-Pathological_formation
and	1848	1851	O
other	1852	1857	O
similar	1858	1865	O
proliferative	1866	1879	B-Pathological_formation
lesions	1880	1887	I-Pathological_formation
.	1887	1888	O

